Stock PEG A PHARMA EQUITY GROUP A/S
Add to a list
To use this feature you must be a member
Log inSign up

News Pharma Equity Group A/S

Equities

PEG A

DK0061155009

Market Closed - Nasdaq Copenhagen
Other stock markets
 03:28:14 2024-04-18 am EDT 		5-day change 1st Jan Change
0.3 DKK 0.00% Intraday chart for Pharma Equity Group A/S +0.67% -30.23%
Apr. 10 Pharma Equity Group A/S announced that it has received DKK 7.6 million in funding CI
Apr. 05 Pharma Equity Group?s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company?s patented drug candidate RNX-051 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Passing of the General Meeting of Pharma Equity Group A/S
GL
The Board of Director's decision to issue convertible loans
GL
Pharma Equity Group A/S announced that it has received DKK 7.6 million in funding
CI
Pharma Equity A/S : Group's subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company's patented drug candidate RNX-051.
PU
Pharma Equity Group’s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company’s patented drug candidate RNX-051.
GL
Pharma Equity Group?s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company?s patented drug candidate RNX-051
CI
Notice convening the annual general meeting in Pharma Equity Group A/S
GL
Pharma Equity Group A/S (PEG) enters into an agreement with Danske Bank on the exercise of market maker in the PEG share, fund code: DK0061155009
GL
Completion of subscription of convertible loans
GL
Correction: Pharma Equity Group A/S - Annual Report 2023
GL
Pharma Equity Group A/S Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Pharma Equity Group A/S Provides Group Earnings Guidance for the Full Year 2024
CI
Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has received notification from the European Patent Office (EPO) regarding the decision to grant their patent for drug compositions for promoting the healing of wounds (RNX-022).
GL
Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has received notification from the European Patent Office (EPO) regarding the decision to grant their patent for drug compositions for promoting the healing of wounds (RNX-022).
AQ
Completion of subscription of convertible loans
GL
The Board of Director's decision to issue convertible loans
GL
Pharma Equity Group A/S announced that it expects to receive DKK 7.1 million in funding
CI
Completion of subscription of convertible loans
GL
Pharma Equity Group A/S announced that it has received DKK 8.914795 million in funding
CI
Notification from the European Patent Office (EPO) regarding the decision to grant their patent for drug compositions aiming to eliminate bacterial promoters of colorectal cancer through intraluminal application (RNX-051).
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PEG A Stock
  4. News Pharma Equity Group A/S